Yao Yinan, Liu Mei, Zang Feng, Yue Ming, Xia Xueshan, Feng Yue, Fan Haozhi, Zhang Yun, Huang Peng, Yu Rongbin
Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
BMJ Open. 2018 Apr 12;8(4):e019406. doi: 10.1136/bmjopen-2017-019406.
The () gene located in the non-classical class-II region may play a role in treatment response to hepatitis C virus (HCV). This study was conducted to explore the role of single nucleotide polymorphisms (SNPs) in in responding to HCV therapy.
All patients were recruited between January 2011 and September 2016 from the Jurong People's Hospital, Jiangsu Province, China.
A total of 346 chronic hepatitis C (CHC) patients who finished the 48-week pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV) treatment were enrolled in this study. All patients were former remunerated blood donors. The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-α/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases.All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-α at a dose of 180 µg once a week with the addition of 800-1000 mg/d RBV according to weight orally for 48 weeks.
The SNPs rs1044429 and rs2284191 and rs2856997 of 18 SNPs were correlated with HCV treatment response in the Chinese Han population. The dominant model indicated that patients carrying favourable genotypes at rs1044429 AA and rs2284191 AA were more likely to achieve sustained virological response (SVR) (OR 1.99, 95% CI 1.25 to 3.19; OR 2.71, 95% CI 1.58 to 4.63, respectively), while patients carrying unfavourable genotypes at rs2856997 GG were less likely to achieve SVR (OR 0.48, 95% CI 0.29 to 0.78).
Genetic variations at rs1044429, rs2284191 and rs2856997 were independent predictors of HCV treatment response in the Chinese Han population.
位于非经典II类区域的（）基因可能在丙型肝炎病毒（HCV）治疗反应中发挥作用。本研究旨在探讨单核苷酸多态性（SNP）在（）基因中对HCV治疗反应的作用。
所有患者于2011年1月至2016年9月期间从中国江苏省句容市人民医院招募。
本研究共纳入346例完成48周聚乙二醇化干扰素-α和利巴韦林（PEG IFN-α/RBV）治疗的慢性丙型肝炎（CHC）患者。所有患者均为既往有偿献血者。患者的纳入标准如下：（1）初治且接受PEG IFN-α/RBV治疗；（2）治疗前血清中HCV RNA存在超过6个月；（3）乙肝（HBV）或HIV感染阴性；（4）无任何其他肝脏疾病。本研究所有参与者均为中国汉族人群，感染HCV基因1b型，接受皮下注射PEG IFN-α，剂量为每周1次180μg，并根据体重口服800 - 1000mg/d利巴韦林，共48周。
18个SNP中的rs1044429、rs2284191和rs2856997与中国汉族人群的HCV治疗反应相关。显性模型表明，rs1044429位点携带有利基因型AA和rs2284191位点携带有利基因型AA的患者更有可能实现持续病毒学应答（SVR）（OR分别为1.99，95%CI为1.25至3.19；OR为2.71，95%CI为1.58至4.63），而rs2856997位点携带不利基因型GG的患者实现SVR的可能性较小（OR为0.48，95%CI为0.29至0.78）。
rs1044429、rs2284191和rs2856997位点的基因变异是中国汉族人群HCV治疗反应的独立预测因素。
